Search for dissertations about: "Substantia Nigra SN"
Showing result 1 - 5 of 14 swedish dissertations containing the words Substantia Nigra SN.
-
1. GDNF gene delivery in an animal model of Parkinson's disease. Long-term effects on intact, injured and transplanted dopamine neurons using lentiviral gene transfer
Abstract : Parkinson's disease is characterized by a progressive degeneration of dopaminergic neurons in the substantia nigra, leading to a loss of dopamine in the target structure striatum and development of motor symptoms, such as bradykinesia, rigidity and tremor. New experimental treatment strategies for Parkinson's disease are aimed at either preventing the degeneration of the dopaminergic neurons, or at restoring dopamine in the striatum by fetal dopaminergic transplants. READ MORE
-
2. Dopamine and the regulation of movements - significance of nigral and striatal dopamine release in normal, hemiparkinsonian and dyskinetic rats
Abstract : Introduction: The nigrostriatal dopamine (DA) containing neurones are a pivotal component in the basal ganglia, a network that regulates movement. Degeneration of these neurones causes the cardinal symptoms of Parkinson’s disease (PD). READ MORE
-
3. United in Diversity : A Physiological and Molecular Characterization of Subpopulations in the Basal Ganglia Circuitry
Abstract : The Basal Ganglia consist of a number of different nuclei that form a diverse circuitry of GABAergic, dopaminergic and glutamatergic neurons. This complex network is further organized in subcircuits that govern limbic and motor functions in humans and other vertebrates. READ MORE
-
4. Experimental Studies of BMP Signalling in Neuronal Cells
Abstract : The developing nervous system depends largely on extracellular cues to shape its complex network of neurons. Classically, neurotrophins are known to be important mediators in this process. READ MORE
-
5. The non-human primate as a model of human parkinsonism
Abstract : The motor deficits seen in Parkinson’s disease (PD) are the result of a loss of catecholaminergic neurons from the substantia nigra (SN) and the associated loss of striatal dopamine. Clinical signs become evident once striatal dopamine levels decline by at least 70-80% and nigral cell numbers by 40%, and worsen with increased duration of the disease. READ MORE